Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa

Haemophilia

Volumn 20, Issue 4, 2014, Pages 527-534

  Santagostino, E ^a   Lentz, S R ^b   Busk, A K ^c   Regnault, A ^d   Iorio, A ^e  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF IOWA   (United States)

^c NOVO NORDISK A S   (Denmark)

^d MAPI Institute   (France)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Haemophilia; Health related quality of life; Prophylaxis; Questionnaires; Turoctocog alfa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; RECOMBINANT FACTOR VIII N8;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; DISEASE SEVERITY; FEMALE; HEMOPHILIA A; HEMOPHILIA QUALITY OF LIFE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME; CLINICAL TRIAL; HEALTH; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEALTH; HEMOPHILIA A; HUMANS; MIDDLE AGED; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84904767678     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12371     Document Type: Article

References (28)

1. Stonebraker JS, Bolton-Maggs PH, Soucie JM, Walker I, Brooker M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16: 20-32.
2. Rodriguez-Merchan EC. Prevention of the musculoskeletal complications of hemophilia. Adv Prev Med 2012; 2012: 201271.
3. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-e47.
4. Berntorp E, Boulyjenkov V, Brettler D et al. Modern treatment of haemophilia. Bull World Health Organ 1995; 73: 691-701.
5. Coppola A, Di CM, De SC. Primary prophylaxis in children with haemophilia. Blood Transfus 2008; 6(Suppl 2): s4-11.
6. National Hemophilia foundation. MASAC (Medical and Scientific Advisory Council) Recommendation 179: MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). Available at http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed June 24, 2013.
7. Khoriaty R, Taher A, Inati A, Lee C. A comparison between prophylaxis and on demand treatment for severe haemophilia. Clin Lab Haematol 2005; 27: 320-3.
8. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
9. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
10. Rosendaal FR, Smit C, Varekamp I et al. Modern haemophilia treatment: medical improvements and quality of life. J Intern Med 1990; 228: 633-40.
11. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24.
12. Khair K, Lawrence K, Butler R, O'Shea E, Christie BA. Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective. Acta Haematol 2008; 119: 115-23.
13. Thim L, Vandahl B, Karlsson J et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010; 16: 349-59.
14. Kulkarni R, Karim FA, Glamocanin S et al. Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19: 698-705.
15. Lentz SR, Misgav M, Ozelo M et al. Results from a large multinational clinical trial (guardian1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19: 691-7.
16. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
17. von Mackensen S, Bullinger M. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia 2004; 10(Suppl 1): 17-25.
18. Riva S, Bullinger M, Amann E, von MS. Content comparison of haemophilia specific patient-rated outcome measures with the international classification of functioning, disability and health (ICF, ICF-CY). Health Qual Life Outcomes 2010; 8: 139.
19. von Mackensen S, Gringeri A, Ravera S et al. Validation of the haemophilia-specific quality of life questionnaire for adult patients with haemophilia (Haem-A-QoL). Haematologica 2005; 90(Suppl. 2): 115-6.
20. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61: 102-9.
21. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 52: 861-73.
22. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999; 37: 469-78.
23. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill Inc, 1994.
24. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-334.
25. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009; 15: 1014-21.
26. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
27. U.S.Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed December 2013.
28. Mantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia 2005; 11: 589-97.